Today: 17 March 2026
Subscribe
Browse Category

BIT:UCG 25 September 2025 - 27 September 2025

Crypto’s Wild 48 Hours: Bitcoin Rebounds, DeFi Breakthroughs, NFT Surprises & Regulation Shake-Ups (Sept 26–27, 2025)

Crypto’s Wild 48 Hours: Bitcoin Rebounds, DeFi Breakthroughs, NFT Surprises & Regulation Shake-Ups (Sept 26–27, 2025)

Bitcoin dropped to around $109,000 amid $1.1 billion in liquidations before rebounding above $110,000 on Friday. Ethereum rose 3.8% to reclaim $4,000 after U.S. inflation data met expectations. Tether is seeking to raise $20 billion at a $500 billion valuation, with SoftBank and ARK Invest reportedly in talks. Nine major European banks announced plans for a euro-backed stablecoin to rival dollar tokens.
27 September 2025
····
Shutdown Jitters, ETF Tsunami & Crypto Power Plays – Top Crypto News (Sept 24–25, 2025)

Shutdown Jitters, ETF Tsunami & Crypto Power Plays – Top Crypto News (Sept 24–25, 2025)

U.S. regulators fast-tracked crypto ETF approvals, with launches expected in early October and Grayscale debuting a Crypto 5 index ETF. Bitcoin and Ether fell mid-week as U.S. shutdown fears grew, with Ether dropping below $4,000. Nine European banks plan a euro stablecoin by 2026. Australia moved to license crypto platforms, while Hong Kong warned against unauthorized stablecoins.
25 September 2025
···

Stock Market Today

  • Eli Lilly Stock Drops 5% After HSBC Downgrade Citing GLP-1 Market Concerns
    March 17, 2026, 1:39 PM EDT. Eli Lilly (LLY) shares fell 5% following a downgrade by HSBC to "reduce" due to concerns over the obesity drug market. HSBC analyst Rajesh Kumar projects the GLP-1 weight-loss drug market, including Lilly's Zepbound and Novo Nordisk's Ozempic, will generate $80-$120 billion annually by 2032-significantly less than the often-cited $150 billion. Price competition and patient discontinuation rates weigh on future revenue. Despite Lilly's plan to offset price cuts with volume growth, HSBC remains skeptical. Trading at 43 times trailing earnings, investors face high valuations with growth estimates capped near 22% annually. This downgrade raises questions about Lilly's ability to sustain its premium valuation amid evolving market dynamics.
Go toTop